RxDoctor Payments Data

David Kaufer, MD

Internal Medicine · San Diego, CANPI 1710082789

Payments from drug & device makers

$2,269in general payments, 2019–2025

Across 59 payments — averaging $38.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$569
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$462
  • Boston Scientific$316
  • AstraZeneca$300
  • Bayer$244
  • Lilly USA, LLC$127
  • plus $252 from 7 others

What the payments were for

  • Travel & lodging$60%
  • Food & beverage$2,263100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,269 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$445,904
Medicare patients
485
Services billed
5,077

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Sensoready PenSecukinumab13$199,077
XifaxanRifaximin26$85,057
JanuviaSitagliptin Phosphate150$84,848
OzempicSemaglutide80$81,230
LinzessLinaclotide105$59,928
JardianceEmpagliflozin94$58,020
EliquisApixaban78$47,659
Atorvastatin Calcium666$27,903
TrulicityDulaglutide22$22,612
TradjentaLinagliptin40$20,829
Icosapent Ethyl97$15,101
Insulin Glargine-Yfgn171$12,472
Omeprazole288$11,735
XareltoRivaroxaban20$11,287
DapagliflozinDapagliflozin Propanediol18$9,885

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$462$85,05726 claims
MerckJanuvia$18$84,848150 claims
AbbVieLinzess, Lumigan$569$65,786127 claims
Lilly USA, LLCTrulicity$127$22,61222 claims
AstraZenecaBrilinta$300$5,41712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →